Immuneering (IMRX) Liabilities and Shareholders Equity (2020 - 2024)
Historic Liabilities and Shareholders Equity for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $68.6 million.
- Immuneering's Liabilities and Shareholders Equity fell 3979.93% to $68.6 million in Q3 2024 from the same period last year, while for Dec 2024 it was $233.6 million, marking a year-over-year decrease of 4797.39%. This contributed to the annual value of $102.6 million for FY2023, which is 1616.67% down from last year.
- Per Immuneering's latest filing, its Liabilities and Shareholders Equity stood at $68.6 million for Q3 2024, which was down 3979.93% from $77.1 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Liabilities and Shareholders Equity registered a high of $166.7 million during Q4 2021, and its lowest value of $38.4 million during Q4 2020.
- Its 5-year average for Liabilities and Shareholders Equity is $110.4 million, with a median of $113.9 million in 2023.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 33386.71% in 2021, then crashed by 3979.93% in 2024.
- Immuneering's Liabilities and Shareholders Equity (Quarter) stood at $38.4 million in 2020, then surged by 333.87% to $166.7 million in 2021, then fell by 26.6% to $122.4 million in 2022, then dropped by 16.17% to $102.6 million in 2023, then tumbled by 33.17% to $68.6 million in 2024.
- Its last three reported values are $68.6 million in Q3 2024, $77.1 million for Q2 2024, and $88.0 million during Q1 2024.